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Abstract
Hypothyroidism is the most common thyroid disorder, affecting about 5% of the general population. Here we present the
current largest genome-wide association study of hypothyroidism, in 3,736 cases and 35,546 controls. Hypothyroidism was
assessed via web-based questionnaires. We identify five genome-wide significant associations, three of which are well
known to be involved in a large spectrum of autoimmune diseases: rs6679677 near PTPN22, rs3184504 in SH2B3, and
rs2517532 in the HLA class I region (p-values 2:8:10{13, 2:6:10{12, and 1:3:10{8, respectively). We also report associations
with rs4915077 near VAV3 (p-value 7:5:10{10) and rs925489 near FOXE1 (p-value 2:4:10{19). VAV3 is involved in immune
function, and FOXE1 and PTPN22 have previously been associated with hypothyroidism. Although the HLA class I region and
SH2B3 have previously been linked with a number of autoimmune diseases, this is the first report of their association with
thyroid disease. The VAV3 association is also novel. We also show suggestive evidence of association for hypothyroidism
with a SNP in the HLA class II region (independent of the other HLA association) as well as SNPs in CAPZB, PDE8B, and CTLA4.
CAPZB and PDE8B have been linked to TSH levels and CTLA4 to a variety of autoimmune diseases. These results suggest
heterogeneity in the genetic etiology of hypothyroidism, implicating genes involved in both autoimmune disorders and
thyroid function. Using a genetic risk profile score based on the top association from each of the five genome-wide
significant regions in our study, the relative risk between the highest and lowest deciles of genetic risk is 2.0.
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Introduction
Hypothyroidism is characterized by deficiencies of thyroid
hormones T3 (triiodothyronine) and T4 (thyroxine). Thyroid
hormones are primarily responsible for the regulation of
metabolism, but also play a major role in development.
Hypothyroidism is typically marked by high thyroid-stimulating
hormone (TSH) levels (usually indicative of impaired thyroid
function). However, this is not always the case. For example,
reduced T3/T4 levels may be caused by insufficient generation of
TSH by the pituitary gland rather than thyroid dysfunction. While
iodine deficiency is the most common cause of hypothyroidism
worldwide, and there are rare forms of congenital hypothyroidism
with a number of genetic causes [1], most cases in the developed
world are due to autoimmune hypothyroidism (e.g., Hashimoto or
Ord thyroiditis). Over the last five years, hundreds of genetic
variants have been found that predispose to various autoimmune
diseases [2], with many shared across multiple autoimmune
diseases [3].
There has been only one published genome-wide association
study (GWAS) of hypothyroidism, carried out in a sample of 1317
hypothyroidism cases and 5053 controls determined algorithmi-
cally from five electronic medical record databases. They found
one association, near FOXE1 (forkhead box E1), also known as
TTF-2 (thyroid transcription factor 2) [4]. Candidate gene studies
have also suggested links between autoimmune hypothyroidism
and PTPN22 (protein tyrosine phosphatase, non-receptor type 22
(lymphoid)), as well as the HLA (human leukocyte antigen) class II
region, CTLA4 (cytotoxic T lymphocyte antigen 4), and 8q23-24
[5–13]. Graves’ disease (another autoimmune thyroid disease,
characterized by hyperthyroidism) has been studied in several
GWAS, with many loci discovered [14–17].
In addition to hypothyroidism, FOXE1 has previously been
associated with thyroid cancer and TSH levels [18]. A second SNP
near this gene (rs755109) has also been associated with TSH levels
in an isolated Pacific Island population [19]. FOXE1 is also
involved in thyroid development and coding mutations cause
congential hypothyroidism [20]. As untreated individuals with
hypothyroidism typically have high TSH levels, it is possible that a
GWAS of TSH levels could detect loci involved in hypothyroid-
ism. These facts raise the question of whether other variants
associated with thyroid function also influence hypothyroidism
risk.
The genetic determinants of TSH levels are partially under-
stood, with several established associations from GWAS, including
PDE8B (phosphodiesterase 8B) [19,21] CAPZB (capping protein
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homeobox 1), also known as TTF-1 (thyroid transcription factor 1)
[18]. CAPZB has also been associated with thyroid volume [23].
These genes have strong links to thyroid function: in addition to
the thyroid transcription factors, PDE8B is primarily expressed in
the thyroid [24] and encodes a phosphodiesterase with a high
affinity for cAMP, which mediates TSH effects in the thyroid [25].
In this paper, we report on the largest GWAS to date of
hypothyroidism. We find five variants significantly associated with
hypothyroidism. Two are non-synonymous variants in genes
associated with many autoimmune diseases (PTPN22 R620W and
SH2B3 (SH2B adaptor protein 3) R262W) and a third is in the
HLA class I region. A fourth is found in an intron of VAV3 (vav 3
guanine nucleotide exchange factor), a gene plausibly involved in
immune function. The final variant is located upstream of the
thyroid transcription factor FOXE1. In addition, among the SNPs
marginally associated with hypothyroidism, we observe associa-
tions with two genes that have been linked to TSH levels: PDE8B
and CAPZB. We also replicate a previously reported association of
CTLA4 with hypothyroidism [13].
Results
We performed a GWAS in 3,736 cases and 35,546 controls
from the customer base of 23andMe, Inc., a personal genetics
company. All participants were of primarily European ancestry
and were at most distantly related to each other. Figure S1 shows
further details about the population structure. Hypothyroidism
was assessed using online self-report. Briefly, participants respond-
ed to questions about their hypothyroidism diagnosis and related
thyroid issues using web-based surveys. We classified as cases
individuals who had been diagnosed with hypothyroidism, had
elevated TSH levels, or were taking thyroid hormone replacement
medication. Controls reported no to at least one of the above
questions and yes to none of them. Participants reporting
hyperthyroidism, thyroid cancer, thyroid removal, or treatment
with radioactive iodine for hyperthyroidism were excluded from
both the cases and controls. Details about the cohort can be found
in Table 1 and the Methods. All analyses were controlled for age,
sex, and five principal components. In addition, a conditional
analysis was performed, adding the five genome-wide significant
SNPs as covariates. Manhattan and quantile-quantile plots for
both analyses are provided in Figures S2 and S3.
Table 2 shows lead SNPs from loci with p-values under 10{6 for
hypothyroidism. Under our threshold for genome-wide signifi-
cance of 5:10{8, five regions are significant (FOXE1, PTPN22,
SH2B3, VAV3, and the HLA region. The strongest association is
with rs925489, with a p-value of 2:4:10{19 and odds ratio (OR) of
0:78, near FOXE1 (Figure S4). This variant has been associated
with hypothyroidism [4]. It is in linkage disequilibrium (LD) with
rs965513, which has been associated with thyroid cancer and TSH
levels [18] and is in weak LD (r2&0:2) with rs1867277, which has
been associated with thyroid cancer and shown to affect FOXE1
transcription [26]. Homozygous loss-of-function mutations in this
gene cause congenital hypothyroidism due to thyroid dysgenesis
and other developmental abnormalities [20].
The second association is with rs6679677, with a p-value of
2:8:10{13 and OR of 1:36 near PTPN22 (Figure S5). The SNP
rs6679677 is in LD (r2&0:9) with rs2476601 (the missense
mutation R620W in PTPN22). This mutation has previously been
associated with Hashimoto thyroiditis in a relatively small
candidate gene study [5]. PTPN22 also has well-established
associations with multiple autoimmune conditions [27], including
type 1 diabetes, rheumatoid arthritis, systemic lupus erythemato-
sus, juvenile idiopathic arthritis [28], Graves’ disease [29,30],
systemic sclerosis [31], and alopecia areata [32].
Next, we see a novel association with rs3184504, a missense
mutation (R262W) in SH2B3, with a p-value of 2:6:10{12 and an
OR of 0:84 (Figure S6). This SNP has not previously been
associated with thyroid disease; however, it has been associated
with a number of autoimmune diseases, including type 1 diabetes
[33], celiac disease [34], rheumatoid arthritis [35], and multiple
sclerosis [36], as well as with hypertension and myocardial
infarction [37]. The T allele of rs3184504 is the variant associated
with increased risk in our data and corresponds to the W allele in
the protein, which is also the risk variant for type 1 diabetes and
rheumatoid arthritis and the protective variant for celiac and
multiple sclerosis.
The next association, which is novel, is with rs4915077, in an
intron of VAV3. This SNP has a p-value of 7:5:10{10 and OR of
1:30. See Figure 1 for SNPs in this region.
Finally, we found two associations between the HLA region and
hypothyroidism (Table 2). The first, rs2517532, is genome-wide
significant with a p-value of 1:3:10{8 and OR of 0.86. It lies in the
HLA class I region, between HLA-E and HLA-C. The second
association (rs2516049, about 2 mb away in the HLA class II
region, near HLA-DRB1) shows only suggestive evidence of
association (p~6:10{7). However, a conditional genome-wide
analysis (conditioning on the five significant associations) reveals
that this second HLA association is independent of the first (see
Figure 2).
Using the five genome-wide significant SNPs, we constructed
risk scores for all participants. In the top decile of risk, there were
555 cases and 3373 controls versus 277 cases and 3650 controls in
the bottom decile, giving a relative risk of approximately 2.0.
Table 3 shows three associations for hypothyroidism with p-
values under 10{4 that are relevant for other conditions. Near
CAPZB (Figure S7), rs1472565 is in moderate LD (r2&0:4) with
rs12091047 (associated with thyroid volume [23]) but not in LD
with rs10917469 (associated with TSH levels [22]). The SNP we
observe near PDE8B, rs4704397 (Figure S8), has also been
associated with TSH levels [21]. Finally, rs231779 near CTLA4
(Figure S9) has been associated with many other autoimmune
diseases as well as with autoimmune hypothyroidism in candidate
gene studies [3,8]. All SNPs with p-values under 10{4 are shown
in Table S1.
Table 1. Cohort statistics.
Number Male Female ƒ45 46–55 56–65 w65 V1 V2 V3
Control 35546 22446 13100 18941 5528 6142 4935 271 15699 19572
Case 3736 953 2783 979 640 1120 997 29 1694 2013
Participants broken down by sex, age, and genotyping platform. V1, V2, and V3 refer to the three platforms used in this study, see Methods.
doi:10.1371/journal.pone.0034442.t001
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diseases, we investigated a list of 107 SNPs that were studied across
7 autoimmune diseases [3]. Among this list, only the CTLA4,
PTPN22, and SH2B3 loci show significant association with
hypothyroidism after correction for 107 multiple tests. See Table
S2 for details for all 107 SNPs.
Discussion
We have found five genome-wide significant associations for
hypothryoidism (near FOXE1, PTPN22, SH2B3, VAV3, and the
HLA class I region) as well as four others with suggestive evidence
of biological interest (near CAPZB, PDE8B, and CTLA4 as well as
in the HLA class II region). Of these, six seem to be involved in
immune function (PTPN22, SH2B3, VAV3, CTLA4, and the two in
HLA) and three in thyroid function (FOXE1, CAPZB, and PDE8B);
see Figure 3. This suggests that while autoimmune loci may play a
predominant role in genetic predisposition for hypothyroidism,
there may be smaller effects due to genes more directly related to
thyroid function and hormone levels.
Three of these associations are novel: the non-synonymous
change R262W in SH2B3, the SNP rs4915077 near VAV3, and
rs2517532 in the HLA class I region. The SH2B3 and HLA
associations reinforce the connection between hypothyroidism and
autoimmune genetics. VAV3 is a guanine nucleotide exchange
factor for Rho guanosine triphosphatases. It has not yet been
associated with autoimmune disease or thyroid function. However,
it has been proposed as the candidate gene in the Idd18.1 region
linked with type 1 diabetes in mouse [38], and the Vav1/Vav2/
Vav3 family is necessary for adaptive immune function in mouse
Table 2. SNPs associated with hypothyroidism at pv10{6.
SNP Chr. Pos. Region Alleles MAF HWE Np -value OR
rs925489 9 99586421 FOXE1 T/C 0.332 0.69 38947 2:4:10{19 0.78 (0.74–0.82)
rs6679677 1 114105331 PTPN22 C/A 0.091 0.34 38959 2:8:10{13 1.36 (1.26–1.48)
rs2476601 1 114179091 PTPN22 G/A 0.092 0.26 39256 3:9:10{13 1.36 (1.25–1.47)
rs3184504 12 110368991 SH2B3 T/C 0.497 0.49 39245 2:6:10{12 0.84 (0.79–0.88)
rs4915077 1 108167539 VAV3 T/C 0.084 0.76 39248 7:5:10{10 1.30 (1.20–1.42)
rs2517532 6 31126386 HLA G/A 0.403 0.094 39225 1:3:10{8 0.86 (0.82–0.91)
rs2516049 6 32678378 HLA T/C 0.307 0.13 39241 6:10{7 1.15 (1.09–1.21)
All genomic positions are given with respect to NCBI build 36.3. Alleles are listed as major/minor and are specified for the forward strand. N refers to the number of
people successfully genotyped for each SNP. Odds ratios are per copy of the minor allele. One SNP is listed per region of the genome with the exception of HLA, which
shows evidence of two independent signals, and PTPN22, for which we have included rs2476601, the non-synonymous change R620W.
doi:10.1371/journal.pone.0034442.t002
Figure 1. SNPs in the VAV3 region. In the plot, circles represent unannotated SNPs, upside-down triangles represent non-synonymous variants,
and boxes with an ‘‘x’’ are SNPs in regions that are highly conserved across 44 placental mammals. Colors depict the squared correlation (r2) of each
SNP with the most associated SNP (i.e., rs4915077, shown in purple). Gray indicates SNPs for which r2 information was missing. Plots were produced
using the LocusZoom program [50].
doi:10.1371/journal.pone.0034442.g001
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regulated in a subset of thyroid tumors [41]. The second,
suggestive association in the HLA class II region, rs2516049, lies
near HLA-DRB1. Non-synonymous variants in HLA-DRB1 have
been associated with autoimmune thyroiditis in humans and in
mice [6].
We have also replicated several previously discovered associa-
tions. FOXE1 has recently been associated with hypothyroidism (as
well as several other thyroid conditions) in a GWAS with 1,317
hypothyroidism cases determined from medical records [4]. Their
strongest association was at rs7850258, with a reported OR of 0.74
(95% confidence interval of 0.67–0.82). For this SNP, we see a
very similar OR of 0.78 (0.74–0.82). We have found one more
association with a variant well known to be involved in
autoimmune disease: R620W in PTPN22. This association was
also seen in Denny et al. [4] (p-value of 5:10{4, OR of 1.29) as
well as in a small candidate gene study of Hashimoto thyroiditis
[5] (OR of 1.77 (1.31–2.40) in a sample of 194 cases and 2064
controls). We observe an OR for this SNP of 1.36 (1.25–1.47),
which is similar to previous studies, despite slightly different
phenotypes.
While many autoimmune diseases share genetic risk factors
[42], there is evidence that these diseases form separate clusters
based on genetics [3,43]. For example, the 620W allele of PTPN22
has a protective effect in Crohn’s disease [44] but is the risk allele
for type 1 diabetes and others [45] (and hypothyroidism as
reported here). SH2B3 also shows opposite directions of effect in
multiple sclerosis and celiac compared to rheumatoid arthritis,
Figure 2. SNPs in the HLA region. (A) shows statistics for the main GWAS, (B) shows statistics conditioned on 5 genome-wide significant SNPs
(rs925489, rs6679677, rs3184504, rs4915077, rs2517532). For details, see Figure 1.
doi:10.1371/journal.pone.0034442.g002
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results begin to place hypothyroidism on the spectrum of
autoimmune disease.
Our web-based design leads to a number of interesting trade-
offs. On the one hand, the ease of online phenotype collection
allows us to cheaply amass a very large study population (e.g.,
3,736 cases in our study, compared to 1,317 cases in the only
previous GWAS of hypothyroidism [4]). On the other hand, due
to the nature of online self-reported data, we did not gather clinical
measures such as TSH levels or hypothyroidism symptoms. The
consequences of potential case misclassification arising from the
unavailability of clinical data may manifest in two different ways. If
some of our reported cases were misclassified at random (i.e., if a
fraction f of the cases were actually controls who randomly
reported having hypothyroidism), then the impact on our study
would be a decrease in power as a consequence of a downward
bias in the odds ratios observed in our study population, with no
increase in false positive rate. In our study, however, the
compensatory gain in power from having a larger sample more
than makes up for the reduction in power due to random
misclassification. For instance, conservatively assuming an f as
high as 0.2, our power to detect the HLA class I association in
Table 2 was 27%; reducing the sample size in half in order to
obtain f~0 results in a power reduction to 15%. In practice, the
close similarity of the odds ratios reported here with previous
estimates suggest that random misclassification is unlikely to
substantially affect our results.
A separate concern is whether a substantial proportion of the
cases in this study were not randomly misclassified controls but
rather individuals who actually exhibited symptoms for a separate
health condition (e.g., elevated TSH levels unrelated to hypothy-
roidism). Our study does not exclude this possibility. For example,
about 7.5% of females and 2.8% of males are estimated to have
elevated TSH levels and 2–3% of individuals are estimated to have
overt symptoms of hypothyroidism [45]. These estimated rates of
hypothyroidism are lower than the 9.5% prevalence of hypothy-
roidism (defined as either elevated TSH levels or hypothyroidism
diagnosis) in our cohort, although the hypothyroidism is generally
thought to be under-diagnosed (or possibly over-diagnosed in a
health-conscious group of participants). As many of the SNPs
discussed here show pleiotropic effects across autoimmune diseases
or thyroid conditions, and as hypothyroidism is difficult to exactly
define in a retrospective, web-based design, ultimately, the loci
discovered here should be further replicated in a more deeply
phenotyped hypothyroidism population, to determine the inter-
play between thyroid function genes and immune system genes
that leads to this disorder.
Methods
Cohort
All participants in the study were customers of 23andMe, Inc., a
personal genetics company, who had been genotyped as part of the
23andMe Personal Genome ServiceH. Individuals included in the
cohort were selected for being of primarily European ancestry, as
determined through an analysis of local ancestry via comparison to
the three HapMap 2 populations, using an unpublished method
substantially similar to Falush et al. [46]. All participants had over
97% of their genome estimated to be most similar to the HapMap
CEU population. This subset was selected as it is the largest
relatively unstructured set within the 23andMe customer base.
A maximal set of unrelated individuals was chosen for the
analysis using a segmental identity-by-descent (IBD) estimation
algorithm (as used in [47]). Individuals were defined as related if
they shared more than 700 cM IBD, including both regions where
the two individuals share either one or both genomic segments
identical-by-descent. This level of relatedness (roughly 20% of the
genome) corresponds approximately to the minimal expected
sharing between first-cousins in an outbred population.
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study protocol and informed
consent form were approved by the external IRB, Ethical and
Independent Review Services (E&I Review), which is accredited
by the Association for the Accreditation of Human Research
Protection Programs (AAHRPP). Informed consent was obtained
from subjects online, in an IRB approved process. Our consent
and privacy statement preclude the sharing of individual-level data
without explicit consent. We have, however, shared summary
statistics for all SNPs with p-values under 10{4 in Table S1.
Table 3. Selected SNPs suggestively associated with hypothyroidism.
SNP Chr. Pos. Region Alleles MAF HWE Np -value OR
rs1472565 1 19,627,617 CAPZB T/C 0.478 0.39 39249 6:3:10{5 1.107 (1.05–1.16)
rs4704397 5 76,554,198 PDE8B G/A 0.390 0.98 21622 2:1:10{6 1.179 (1.10–1.26)
rs231779 2 204,442,732 CTLA4 C/T 0.366 0.81 39254 7:10{6 1.126 (1.07–1.19)
Three SNPs with connections to other conditions that are suggestively associated with hypothyroidism. CAPZB and PDE8B have been associated with TSH levels and
CTLA4 with a variety of autoimmune diseases, including autoimmune hypothyroidism. See Table 2 for nomenclature, Table S1 for all SNPs with pv10{4 and Table S2 for
107 SNPs involved in autoimmune disease.
doi:10.1371/journal.pone.0034442.t003
Figure 3. Summary of results. Regions associated with hypothy-
roidism classified by signficance level (genome-wide or suggestive),
known function (thyroid versus autoimmune), and whether they had
previously been associated with hypothyroidism.
doi:10.1371/journal.pone.0034442.g003
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For the 23andMe cohort, DNA extraction and genotyping were
performed on saliva samples by National Genetics Institute (NGI),
a CLIA-certified clinical laboratory and subsidiary of Laboratory
Corporation of America. Samples were genotyped on one of three
different platforms. About half of the participants were genotyped
on one of two platforms based on the Illumina HumanHap550+
BeadChip (called V1 and V2 in Table 1), which included SNPs
from the standard HumanHap550 panel augmented with a
custom set of approximately 25,000 SNPs selected by 23andMe.
Two slightly different versions of this platform were used, as
described in [47]. The remaining participants were genotyped on
the Illumina OmniExpress+ Bead Chip. This platform has a base
set of 730,000 SNPs. It was augmented by approximately 250,000
SNPs to make it approximately a superset of the HumanHap550+,
as well as a custom set of about 30,000 SNPs. This platform was
called V3 in Table 1. With the exception of the SNP rs4704397
near PDE8B (a V3-only SNP), all SNPs discussed here appeared at
least on the V2 and V3 platforms that were used to genotype the
vast majority of samples. Every sample that failed to reach a
98.5% call rate for SNPs on the standard platforms was re-
analyzed. Individuals whose analyses failed repeatedly were re-
contacted by 23andMe customer service to provide additional
samples, as is done for all 23andMe customers. Our quality control
procedures include genotyping the HapMap sample on our
platforms and discarding discordant SNPs, manual examination
of thousands of cluster plots, filtering based on Mendelian
discordance in thousands of genotyped trios, filtering by Hardy-
Weinberg, as well as independent validation of many probes.
Quality control procedures for the genotyping are described in
more detail in [47].
SNPs with a call rate under 95% or minor allele frequency
under 0.01 were excluded from analysis. Call rates were calculated
on a per-platform basis. Additionally, SNPs with Hardy-Weinberg
p-values [48] less than than 10{20 were excluded. Altogether,
870,065 SNPs (on the union of the two platforms) were retained
with an average call rate of 99.78%.
Phenotyping
Participants were able to fill out web-based questionnaires
whenever they logged into their 23andMe accounts. Participants
answered some of the following questions:
N Have you ever been diagnosed by a doctor with any of the
following thyroid conditions? (asked as part of a medical
history questionnaire)
– Hyperthyroidism
– Hypothyroidism
N Have you been diagnosed with any of the following? (asked as
part of a questionnaire on baldness)
– Hyperthyroidism (overactive thyroid)
– Hypothyroidism (underactive thyroid)
N Have you ever been diagnosed with hypothyroidism (under-
active thyroid)?
N Do you currently take medication for hypothyroidism (low
thyroid hormone levels)?
N Have you ever been told by a doctor that your thyroid
stimulating hormone (TSH) levels were elevated, indicating
hypothyroidism?
N Have you ever been diagnosed with thyroid cancer?
N Have you ever received radioactive iodine treatment for goiter
or hyperthyroidism (overactive thyroid)?
N Have you ever had all or part of your thyroid surgically
removed?
N Have you ever been diagnosed by a doctor with any of the
following common cancers? (asked as part of a medical history
questionnaire)
– Thyroid cancer
Cases answered yes to hypothyroidism or to elevated TSH levels
or to taking medication for hypothyroidism. Controls answered no
to at least one of the qualifying questions and yes to none of them.
Individuals reporting hyperthyroidism or thyroid cancer or
treatment with radioactive iodine or thyroid removal were
excluded, as all of these could cause hypothyroidism or could
signal Graves’ disease.
As customers of 23andMe, all participants had the opportunity
to view reports based on their genetic information on over 100
traits and diseases. Among these diseases were reports on thyroid
cancer (covering the FOXE1 and NKX2-1 SNPs from [18]) and
Hashimoto thyroiditis (covering PTPN22). The context in which a
question is asked can influence responses, as we have seen in a very
different context in a previous paper [47]. While it is unlikely that
a predicted high or low risk for thyroid cancer would lead to
misreport of hypothyroidism, we sought to rule out any such bias
in this case. Indeed, for PTPN22, there was no evidence of a
difference in ORs for rs2476601 and hypothyroidism for people
viewing their results before or after answering survey questions
(p~0:89 for interaction).
Statistical analysis
For the association analysis, all p-values were calculated using a
likelihood ratio test for the logistic regression model, adjusting for
sex, age, and projections onto the first five principal components of
the genotype data matrix. The principal components used were
calculated within the subset of 23andMe customers with primarily
Europeanancestry,asdescribedpreviously[49].FigureS1showsthe
first two principal components with self-reported ancestry overlayed
forasubsetofparticipants.The inflation factorwithoutanyprincipal
components included in the model was 1.032. After including five,
this decreased slightly to 1.029. See Figure S3 for the quantile-
quantile plot. The phenotypic status of each individual was coded as
0 for unaffected individualsand 1 for affected individuals. Genotypes
were coded 0, 1,or 2, to indicate the number of minoralleles present
for the tested SNP (corresponding to a log-additive model of
association). For the conditional analysis, the 5 SNPs found to be
genome-wide significant were added as predictors to the model. For
SNPs appearing on a subset of genotyping platforms, analyses were
restricted to individuals who were typed. Reported odds ratios for
eachSNP relativetothe minor alleleweredefined as theexponential
of the regression coefficients, and the alleles used throughout refer to
the plusstrand of NCBI build 36.3of the humangenome. Weused a
cutoff for genome-wide significance of 5:10{8 (corresponding to a
Bonferroni correction assuming 1 million independent tests).
Supporting Information
Figure S1 Projections onto first two principal compo-
nents for all participants in this study. The country codes
are based on self-reported ancestry from a subset of 3363
participants. These participants reported four grandparents born
in the given country (or in the case of ‘‘AJ’’, four grandparents of
Novel Associations for Hypothyroidism
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34442Ashkenazi Jewish ancestry). The label for a country is placed at the
median position of all participants reporting such ancestry, and the
size is proportional to the number of such reports. Note that the
label size is not proportional to the actual density of each subgroup
in the study (the densities are approximately 85% northern
European and 5% each Ashkenazi, eastern European, and
southern European).
(TIFF)
Figure S2 Manhattan plots. (A) Negative log p-values for
SNPs by genome position. Genome-wide significant SNPs are
shown in red. (B) Same for conditional analysis adding 5 genome-
wide signficiant SNPs (rs925489, rs6679677, rs3184504,
rs4915077, rs2517532) as covariates.
(TIFF)
Figure S3 Quantile-quantile plot. Observed p-values versus
theoretical p-values under the null hypothesis of no association.
The genomic control inflation factor for the study was 1:03 and is
indicated by the red line. (A) Genome-wide analysis. (B)
Conditional analysis with five SNPs included as covariates.
(TIFF)
Figure S4 SNPs in the FOXE1 region. In the plot, circles
represent unannotated SNPs, upside-down triangles represent
non-synonymous variants, and boxes with an ‘‘x’’ are SNPs in
regions that are highly conserved across 44 placental mammals.
Colors depict the squared correlation (r2) of each SNP with the
most associated SNP (i.e., rs925489, shown in purple). Gray
indicates SNPs for which r2 information was missing. Plots were
produced using the LocusZoom program.
(TIFF)
Figure S5 SNPs in the PTPN22 region. For details, see
Figure S4.
(TIFF)
Figure S6 SNPs in the SH2B3 region. For details, see Figure
S4.
(TIFF)
Figure S7 SNPs in the CAPZB region. For details, see Figure
S4.
(TIFF)
Figure S8 SNPs in the PDE8B region. For details, see Figure
S4.
(TIFF)
Figure S9 SNPs in the CTLA4 region. For details, see Figure
S4.
(TIFF)
Table S1 SNPs with p-values under 10{4. All genomic
positions are given with respect to NCBI build 36.3. Alleles are
listed as major/minor and are specified for the forward strand. N
refers to the number of people successfully genotyped for each
SNP. Odds ratios are per copy of the minor allele.
(XLS)
Table S2 SNPs identified in other autoimmune diseas-
es. The 107 SNPs studied across 7 autoimmune diseases in
Cotsapas et al., 2011. Under a threshold of 0:05
107 &4:7:10{4 for
significance, only PTPN22, SH2B3, and CTLA4 are significant. See
Table S1 for details on columns.
(XLS)
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